Schneyer Mark C.'s Form 4 filing
Acadia Pharmaceuticals Inc (ACAD) · filed Sep 16, 2025
- Accession no.
- 0001899977-25-000004
- Filed
- Sep 16, 2025
- Trade date
- Sep 12-15, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $82.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schneyer Mark C.CIK 0001899977 | Officer (EVP, CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | Common Stock | AGrant or awardAcquired | +6,815 | $0.00F1 | $0 | 46,945 | Direct | |
| Sep 15, 2025 | Common Stock | SSaleDisposed | −3,498 | $23.65 | −$82,727.7 | 43,447 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target.
Referenced by the price of 1 transaction in Table I.